These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8255684)

  • 21. Exogenous surfactants in a piglet model of acute respiratory distress syndrome.
    Sood SL; Balaraman V; Finn KC; Britton B; Uyehara CF; Easa D
    Am J Respir Crit Care Med; 1996 Feb; 153(2):820-8. PubMed ID: 8564138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs.
    Cummings JJ; Holm BA; Hudak ML; Hudak BB; Ferguson WH; Egan EA
    Am Rev Respir Dis; 1992 May; 145(5):999-1004. PubMed ID: 1586078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant.
    Goldman SL; Bosque E; McCann E; Lewis K
    J Pediatr; 1992 Feb; 120(2 Pt 2):S25-8. PubMed ID: 1735847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of morphine and pancuronium on lung volume and oxygenation in premature infants with hyaline membrane disease.
    Miller J; Law AB; Parker RA; Sundell H; Silberberg AR; Cotton RB
    J Pediatr; 1994 Jul; 125(1):97-103. PubMed ID: 8021797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease.
    Phibbs RH; Ballard RA; Clements JA; Heilbron DC; Phibbs CS; Schlueter MA; Sniderman SH; Tooley WH; Wakeley A
    Pediatrics; 1991 Jul; 88(1):1-9. PubMed ID: 2057244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung function in prematurely delivered rabbits treated with a synthetic surfactant.
    Tooley WH; Clements JA; Muramatsu K; Brown CL; Schlueter MA
    Am Rev Respir Dis; 1987 Sep; 136(3):651-6. PubMed ID: 3307569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of Exosurf Neonatal, a synthetic surfactant, in the treatment of respiratory distress syndrome in the newborn].
    Mikhel'sonVA ; Grebennikov VA; Belaĭ VA; Everstova TN
    Anesteziol Reanimatol; 1995; (1):4-7. PubMed ID: 7605034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate improvement in lung volume after exogenous surfactant: alveolar recruitment versus increased distention.
    Goldsmith LS; Greenspan JS; Rubenstein SD; Wolfson MR; Shaffer TH
    J Pediatr; 1991 Sep; 119(3):424-8. PubMed ID: 1880658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Energy expenditure during synthetic surfactant replacement therapy for neonatal respiratory distress syndrome.
    Hazan J; Chessex P; Piedboeuf B; Bourgeois M; Bard H; Long W
    J Pediatr; 1992 Feb; 120(2 Pt 2):S29-33. PubMed ID: 1735848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
    Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
    N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surfactant replacement therapy: issues related to currently available preparations.
    Bose G
    Neonatal Netw; 1992 Jun; 11(4):vii-xii. PubMed ID: 1608367
    [No Abstract]   [Full Text] [Related]  

  • 32. Exosurf rescue surfactant improves high ventilation-perfusion mismatch in respiratory distress syndrome.
    Billman D; Nicks J; Schumacher R
    Pediatr Pulmonol; 1994 Nov; 18(5):279-83. PubMed ID: 7898965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the changes in the a/A oxygen ratio after administration of two surfactants for the treatment of neonatal respiratory distress syndrome.
    Bassiouny MR; Remo C; Cherian E
    J Trop Pediatr; 1997 Feb; 43(1):38-41. PubMed ID: 9078827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
    Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Artificial surfactant attenuates hyperoxic lung injury in primates. I. Physiology and biochemistry.
    Huang YC; Sane AC; Simonson SG; Fawcett TA; Moon RE; Fracica PJ; Menache MG; Piantadosi CA; Young SL
    J Appl Physiol (1985); 1995 May; 78(5):1816-22. PubMed ID: 7649917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources.
    Rossello JD; Hayward PE; Martell M; Del Barco M; Margotto P; Grandzoto J; Bastida J; Peña J; Villanueva D
    J Perinat Med; 1997; 25(3):280-7. PubMed ID: 9288665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits.
    Sherman MP; Campbell LA; Merritt TA; Long WA; Gunkel JH; Curstedt T; Robertson B
    J Pediatr; 1994 Dec; 125(6 Pt 1):939-47. PubMed ID: 7996369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing surfactant products.
    Prevost RR
    Clin Pharm; 1991 Dec; 10(12):909, 911. PubMed ID: 1773577
    [No Abstract]   [Full Text] [Related]  

  • 39. Surfactant replacement therapy in neonates less than 32 weeks gestation: effect on neonatal intensive care resource utilization.
    Diwaker K; Roberts S; John E
    J Paediatr Child Health; 1993 Dec; 29(6):434-7. PubMed ID: 8286159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for retinopathy of prematurity after surfactant treatment.
    Brunner-Di Pietro D; Bossi E; Koerner F
    Eur J Pediatr; 1995; 154(9 Suppl 4):S90-4. PubMed ID: 8529721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.